Thalidomide

From Glioblastoma Treatments
Revision as of 02:18, 20 March 2024 by Lazy (talk | contribs) (Created page with "{{TreatmentInfo |drug_name=Thalidomide |FDA_approval=Yes (for leprosy and multiple myeloma) |used_for=Investigational use in various cancers due to antiangiogenic and immunomodulatory properties |clinical_trial_phase=Ongoing optimization of thalidomide analogues |common_side_effects=Deep vein thrombosis, peripheral neuropathy, constipation, somnolence, pyrexia, pain, teratogenicity |OS_with=Not specified; ongoing studies for cancer-specific outcomes |PFS_with=Not specifi...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search
Property Information
Drug Name Thalidomide
FDA Approval Yes (for leprosy and multiple myeloma)
Used for Investigational use in various cancers due to antiangiogenic and immunomodulatory properties
Clinical Trial Phase Ongoing optimization of thalidomide analogues
Clinical Trial Explanation Not specified
Common Side Effects Deep vein thrombosis, peripheral neuropathy, constipation, somnolence, pyrexia, pain, teratogenicity
OS without Not specified
OS with Not specified; ongoing studies for cancer-specific outcomes
PFS without Not specified
PFS with Not specified; research focuses on enhancing therapeutic profiles while minimizing toxicity
Usefulness Rating 3
Usefulness Explanation Not specified
Toxicity Level Not specified
Toxicity Explanation Not specified

Notes: Recent advances in thalidomide-related compounds target anticancer efficacy with reduced side effects. These developments suggest thalidomide analogues could become a promising therapeutic alternative for cancer treatment, enhancing the drug's applicability beyond its current FDA-approved uses. Continued research aims to refine these compounds to maximize benefits and minimize risks.


From Ben Williams Book: Not specified

Loading comments...
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Thalidomide&oldid=62"